Please login to the form below

Not currently logged in
Email:
Password:

Industry veteran Louis Nisbet joins Sygnature board

Brings experience from Roche, Glaxo and SmithKline

Sygnature Louis NisbetSygnature Discovery has appointed Dr Louis Nisbet to its board as a non-executive director.

The UK-based clinical research organisation (CRO) will benefit from Dr Nisbet's extensive experience in the life sciences industry, which includes spells in research at Roche, Glaxo and SmithKline.

Following this period, he became an entrepreneur, helping to found companies such as Xenova, Brax and InTouch with Health.

Dr Nisbet's current roles include serving as venture partner with Kurma Life Sciences Partners and chairman of the science park BioCity in Nottingham, UK.

Sygnature's CEO Dr Simon Hirst commented that Dr Nisbet joins the board at a time of growth for the company, which includes the recent addition of in vitro bioscience to its capabilities and enhancing its computational chemistry and informatics capabilities.

“Louis will provide us with advice and guidance as we continue our expansion and evolution as a business,” said Dr Hirst.

1st October 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....